Verve Therapeutics
Clinical trials sponsored by Verve Therapeutics, explained in plain language.
Gene-editing biotech targeting cardiovascular disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Editing shot could slash cholesterol for good Results expected Oct 2026 (estimated)
-
Gene-Editing shot could slash cholesterol for good
Disease control Recruiting nowThis early-stage trial tests a single IV dose of VERVE-102, a gene-editing drug designed to permanently lower LDL (bad) cholesterol by turning off a specific gene in the liver. It involves 85 adults with inherited high cholesterol or early heart disease who still need lower chole…
Phase 1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Gene-Editing shot aims to slash cholesterol that drugs Can't touch
Disease control Recruiting nowThis early-stage study tests a single dose of VERVE-201, a gene-editing therapy, in 36 adults with dangerously high cholesterol and triglycerides that don't respond to standard treatments. The treatment aims to permanently turn off a liver gene (ANGPTL3) to lower blood fats. The …
Phase 1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC